Correlating serum micrornas and clinical parameters in amyotrophic lateral sclerosis

Radhika Raheja, Keren Regev, Brian C. Healy, Maria Antonietta Mazzola, Vanessa Beynon, Felipe Von Glehn, Anu Paul, Camilo Diaz-Cruz, Taha Gholipour, Bonnie I. Glanz, Pia Kivisakk, Tanuja Chitnis, Howard L. Weiner, James D. Berry, Roopali Gandhi*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Introduction: Amyotrophic lateral sclerosis (ALS) is a debilitating neurologic disorder with poor survival rates and no clear biomarkers for disease diagnosis and prognosis. Methods: We compared serum microRNA (miRNA) expression from patients with ALS with healthy controls and patients with multiple sclerosis and Alzheimer disease. We also correlated miRNA expression in cross-sectional and longitudinal cohorts of ALS patients with clinical parameters. Results: We identified 7 miRNAs (miR-192-5p, miR-192-3p, miR-1, miR-133a-3p, miR-133b, miR-144-5p, miR-19a-3p) that were upregulated and 6 miRNAs (miR-320c, miR-320a, let-7d-3p, miR-425-5p, miR-320b, miR-139-5p) that were downregulated in patients with ALS compared with healthy controls, patients with Alzheimer disease, and patients with multiple sclerosis. Changes in 4 miRNAs (miR-136-3p, miR-30b-5p, miR-331-3p, miR-496) correlated positively and change in 1 miRNA (miR-2110) correlated negatively with changes in clinical parameters in longitudinal analysis. Discussion: Our findings identified serum miRNAs that can serve as biomarkers for ALS diagnosis and progression. Muscle Nerve 58: 261–269, 2018.

Original languageEnglish
Pages (from-to)261-269
Number of pages9
JournalMuscle and Nerve
Issue number2
StatePublished - Aug 2018
Externally publishedYes


  • ALS
  • biomarkers
  • disease comparisons
  • longitudinal analysis
  • microRNA
  • serum


Dive into the research topics of 'Correlating serum micrornas and clinical parameters in amyotrophic lateral sclerosis'. Together they form a unique fingerprint.

Cite this